We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medgenics(Regs) | LSE:MEDG | London | Ordinary Share | COM SHS USD0.0001 (REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 302.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Medgenics (AIM:MEDG) (AIM:MEDU) is pleased to announce its unaudited half-yearly results for the six months ended 30 June 2009.
Highlights for the period
Financial Summary (unaudited)
Dr. Andrew Pearlman, Chief Executive Officer of Medgenics, said:
“During the first half of 2009 Medgenics has drawn growing encouragement from the continuing positive results of the Biopump anaemia study. EPODURE has demonstrated months of continuous treatment in nearly all the patients, with one who will shortly be celebrating an unprecedented full year of sustained protein therapy from a single administration. Besides demonstrating the potential of EPODURE as an anaemia treatment, we believe these results also provide powerful proof of the broader concept of Biopump as a method of sustained protein therapy. We are pleased by the significant progress with potential partners and institutional investors which gives us great hope that this will yield concrete results in the coming months. The raising of nearly $1 million of additional operating funds through the issuance of convertible debentures and warrant exercises was also an important development. Meanwhile, the Company continues its focused efforts to raise additional funds in the coming months to enable it to support its existing operations, expand the clinical trial and its other operations and to realize the potential of the great opportunities it now has."
1 Year Medgenics(Regs) Chart |
1 Month Medgenics(Regs) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions